S1310 Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer.(S1310)


Primary Objective: a. To assess overall survival (OS) in patients with refractory advanced biliary cancer randomized to Arm 1: trametinib compared to those randomized to Arm 2: Chemotherapy (either 5-fluorouracil and leucovorin or capecitabine). Secondary Objectives: a. To determine the frequency and severity of adverse events of trametinib in this patient population. b. To assess response rate (RR) and progression-free survival (PFS) in patients randomized to Arm 1: trametinib and patients randomized to Arm 2: Chemotherapy (5-FU or capecitabine in this patient population).


MEK Inhibitor, Trametinib, Capecitabine, Refractory, Biliary Cancer

Principal Investigator

Thomas J George, M.D.



Contact Information


Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at CTSI-Studies-L@lists.ufl.edu.

Other Resources

  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams